Posted by Michael Wonder on 26 Feb 2024
BeiGene receives positive CHMP opinion for tislelizumab as treatment for non-small-cell lung cancer
26 February 2024 - Recommendation based on results of three Phase 3 clinical trials demonstrating benefit of tislelizumab as a first- and second-line treatment for patients with non-small-cell lung cancer.
BeiGene today announced that the CHMP of the EMA issued a positive opinion recommending approval of tislelizumab as a treatment for non-small-cell lung cancer across three indications.
